Glutathione, a compound that is produced in the liver, is the body’s most essential antioxidant, and its ability to neutralize free radicals in cells and aids in detoxification processes has highlighted it as a promising therapeutic for a wide range of diseases and disorders, including many challenging neurological conditions. When patients consider trying a new therapeutic like glutathione, one of the first things that comes to mind is the question of potential side effects. Regardless of the purported health benefits of this therapeutic, it may not be worth integrating it into a treatment strategy if the side effects are so debilitating that they outweigh the benefits. One health treatment option that has raised patient concerns about potential side effects is glutathione IV therapy. Specifically, concerned patients may worry that direct injection into the bloodstream could lead to off-target side effects.
So far, there is no data to indicate that this is the case. However, there are lifestyle-related impacts to glutathione IV therapy that makes it less preferable for some of the patient populations who can benefit most from the compound, like those with Parkinson’s disease and autism spectrum disorder, which makes it less convenient than alternatives like oral supplementation. Therefore, as supplement delivery technology continues to advance, it may make more sense for patients to start using oral glutathione supplements alongside IV therapy.
Existing Data on Glutathione IV Therapy Side Effectsin the 1990’s, and they observed no indications of potentially adverse outcomes. In fact, their only serious concern was that glutathione had a relatively short half-life in the bloodstream, which could potentially limit the duration of its efficacy. These early results regarding glutathione safety and tolerability have been supported by more recent clinical studies. For example, in a 2009 pilot evaluation of an intravenous glutathione treatment for patients with Parkinson’s disease at the University of South Florida, researchers reported that glutathione IV therapy was “well tolerated” and posed “no safety concerns.” A 2017 case report yielded similar results, with the patient complaining of no adverse effects upon intravenous glutathione administration. While some researchers point out that the overall body of literature on the safety of glutathione IV therapy is lacking, the studies that have been conducted all indicate that glutathione IV therapy is not likely to cause the patient to experience side effects.
Lifestyle-Related Impacts on Relevant Patient Populations
Nevertheless, when deciding whether or not to integrate glutathione IV therapy into a treatment strategy for a condition like Parkinson’s disease or autism, it is important to recognize some of the other ways that intravenous administration can impact a patient’s life, in the same way that side effects would. Consider the fact that, in all of the studies that have suggested that glutathione can be a valuable therapeutic for patients with Parkinson’s disease, it has been administered at least once or twice a day. On top of the mobility challenges already facing patients with Parkinson’s disease, the obligation to get a daily glutathione IV can make it even harder to maintain an independent lifestyle. This makes oral supplementation an appealing supplement for these patients.
Similarly, while early studies suggest that glutathione administration may have benefits for patients with autism spectrum disorder, it may not be the optimal treatment solution when it comes to the patient’s lifestyle concerns. One of the most common symptoms of autism is a high level of sensory sensitivity, which can make the very process of intravenous drug administration a major challenge for patients and parents alike. Therefore, because of the potential hassle of IV administration, clinicians and parents may want to consider how a complementary oral glutathione supplement may be integrated into the treatment strategy.
The Growing Promise of Oral Glutathione Supplements as Alternatives to IV Therapythe development of advanced delivery systems for glutathione. Thus, today’s supplements can reach brain cells, and other cells outside the GI tract, so glutathione IV therapy may not actually be necessary. Moreover, these new delivery systems may also help address issues related to the short half-life of glutathione, giving today’s advanced supplements the potential to offer longer-lasting benefits for patients.
While future studies may provide more conclusive data on the side effects of glutathione–whether administered intravenously or orally–today’s clinicians, patients, and parents can be relatively confident that treatment with the compound is unlikely to lead to adverse effects. However, in patient populations for whom daily IV administration may be a significant lifestyle disruption, oral supplementation may be a valuable addition to an effective treatment strategy.
Aebi S, Assereto R, Lauterburg BH. 1991. High-dose intravenous glutathione in man. Pharmacokinetics and effects on cysteine in plasma and urine. European Journal of Clinical Investigation. 21(1):103-10. https://www.ncbi.nlm.nih.gov/pubmed/1907548/
Davids LM, Van Wyk JC, Khumalo NP. 2016. Intravenous glutathione for skin lightening: Inadequate safety data. South African Medical Journal. 106(8):782-6. https://www.ncbi.nlm.nih.gov/pubmed/27499402
Fukugawa NK, Ajami AM, Young VR. 1996. Plasma methionine and cysteine kinetics in response to an intravenous glutathione infusion in adult humans. American Journal of Physiology. 270(2 Pt 1):E209-14. https://www.ncbi.nlm.nih.gov/pubmed/8779940
Hauser RA, Lyons KE, McClain T, Carter S, Perlmutter D. 2009. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson’s disease. Movement Disorders. 24(7):979-83. https://www.ncbi.nlm.nih.gov/pubmed/19230029
Kern JK, Geier DA, Adams JB, Garver CR, Audhya T, Geier MR. 2011. A clinical trial of glutathione supplementation in autism spectrum disorders. Medical Science Monitor. 17(12):CR677-682. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3628138/
King LA, Horak FB. 2009. Delaying mobility disability in people with Parkinson disease using a sensorimotor agility exercise program. Physical Therapy. 89(4):384-393. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2664996/
Marco EJ, Hinkley LBN, Hill SS, Nagarajan SS. 2011. Sensory processing in autism: A review of neurophysiologic findings. Pediatric Research. 69(5 Pt 2):48R-54R. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3086654/
Otto M, Magurs T, Langland JO. 2017. The use of intravenous glutathione for symptom management of Parkinson’s disease: A case report. Alternative Therapies in Health and Medicine. https://www.ncbi.nlm.nih.gov/pubmed/29101773
Pizzorno J. 2014. Glutathione! Integrative Medicine: A Children’s Journal. 13(1):8-12. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4684116/